Structure Therapeutics
Xichen Lin has a significant amount of work experience in the pharmaceutical industry. Xichen currently serves as the Chief Scientific Officer at Structure Therapeutics since July 2019. Prior to this role, they worked at a company called "诺和诺德" from 2016 to 2019 as the Head of External Innovation, Asia Pacific. Before joining "诺和诺德," Xichen held various positions at "鄧蘭素史克公司" from 2002 to 2016. Xichen'sroles there included Head of Neuroinflammation DPU, Director, Head of Chemistry, Neuroinflammation DPU, Manager/Associate Director of Medicinal Chemistry, and Principal Scientist/Team Leader.
Xichen Lin obtained a Ph.D. degree in Organic Synthesis, Total Synthesis, and New Methodology Development from Penn State University, where they studied from 1997 to 2002. Prior to that, they earned a Bachelor of Science (BS) degree in Chemistry from Peking University, where they focused on drug design based on computer modeling and simulation from 1992 to 1997.
This person is not in any offices
Structure Therapeutics
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations inbiologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.